Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Chemo-immunotherapy in Post-Consolidation Neuroblastoma
NCT04385277Phase 2Active, not recruiting
- Sponsor
- Children's Oncology Group
- Start
- Dec 2020
- Primary completion
- Jun 2023
- Modality
- Nanoparticles, Monoclonal Antibodies, Small Molecules
- Countries
- 4
01
Overview
A Phase 2 trial of dinutuximab, irinotecan hydrochloride liposome injection (II) + temozolomide + bevacizumab, temozolomide in neuroblastoma, sponsored by Children's Oncology Group. Started Dec 2020; status: active, not recruiting.
02
Drugs
dinutuximabirinotecan hydrochloride liposome injection (II) + temozolomide + bevacizumabtemozolomide
03
Conditions
neuroblastoma
Beyond the preview
Go deeper on NCT04385277.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04385277.